Independent directory Public ClinicalTrials.gov records United States
Location Directory

Clinical trials in Houston, Texas

This page shows live ClinicalTrials.gov search results for Houston, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 1:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
22539
Shown on this page
12
Current sort
Recently updated
Location scope
Houston, TX
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Houston, Texas. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 793–804 of 22,539 matching trials in Houston, TX.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Houston

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Conditions
Attention-deficit/Hyperactivity Disorder, Emotional Dysregulation
Interventions
Centanafadine XR
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
16
States / cities
Gainesville, Florida • Jacksonville, Florida • Maitland, Florida + 13 more
Conditions
Renal Cell Carcinoma
Interventions
Ipilimumab, Nivolumab, Ciforadenant
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania • Houston, Texas
Conditions
Multiple Myeloma
Interventions
Linvoseltamab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
13
States / cities
Los Angeles, California • Orange, California • Denver, Colorado + 9 more
Conditions
Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
Interventions
Tarlatamab, Durvalumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
563 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
37
States / cities
Mobile, Alabama • Los Angeles, California • New Haven, Connecticut + 32 more
Conditions
Schizophrenia, Autism-Related Irritability
Interventions
KarXT, KarX-EC
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
5 Years to 17 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
58
States / cities
Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 48 more
Conditions
Tricuspid Regurgitation (TR)
Interventions
Tricuspid Transcatheter Edge-to-Edge Repair (TEER)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
8
States / cities
Phoenix, Arizona • La Jolla, California • Chicago, Illinois + 5 more
Conditions
Chronic Kidney Disease and Hypertension
Interventions
Baxdrostat/dapagliflozin, Placebo/dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
133
States / cities
Fairhope, Alabama • Sun City, Arizona • Tucson, Arizona + 117 more
Conditions
NASH With Fibrosis, MASH With Fibrosis
Interventions
Efruxifermin, Placebo
Drug
Lead sponsor
Akero Therapeutics, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
198
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 160 more
Conditions
Hypogonadism, Male
Interventions
Testosterone enanthate
Combination Product
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
12 Years to 17 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
22
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 18 more
Conditions
Visual Acuity
Interventions
Senofilcon A, Nelfilcon A
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
40 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
11
States / cities
Longwood, Florida • Roswell, Georgia • St Louis, Missouri + 8 more
Conditions
Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma
Interventions
Zoldonrasib, Placebo, Oxaliplatin, Leucovorin (Calcium Folinate), 5-Fluorouracil, Irinotecan, Gemcitabine (GEM), Nab-paclitaxel
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
18
States / cities
Phoenix, Arizona • Tucson, Arizona • New Haven, Connecticut + 14 more
Recruiting Phase 2 Interventional

Pan Tumor Rollover Study

NCT03899155
Conditions
Cancer
Interventions
Nivolumab, Ipilimumab, Cabozantinib, Trametinib, Relatlimab, Nivolumab + Relatlimab, Capecitabine, Bevacizumab, Temozolomide, Rucaparib, Daratumumab, Regorafinib, Leucovorin, Fluorouracil, Oxaliplatin, Enzalutamide, Sunitinib, Pemetrexed, Pembrolizumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
59
States / cities
Huntsville, Alabama • Tucson, Arizona • Lynwood, California + 46 more